Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Replagal Advisory Committee Will Include Closed Door Session On Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.

You may also be interested in...



Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated

Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.

Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated

Replagal seemed destined for quick approval – the enzyme replacement therapy was already distributed free of charge to U.S. patients in response to short supples of Genzyme’s Fabrazyme. But FDA has signaled otherwise, and Shire doesn’t think Replagal warrants the effort.

Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.

Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel